GlassScriptPhysician profile
Tze Yan Chan
NPI 1376579706
$13,099.67
in general payments reported to CMS, 2019-2025
52 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $2,075 · 2021: $2,263 · 2022: $2,147 · 2023: $1,478 · 2024: $1,344 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.35 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,837.39 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,791.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,101.94 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $827.44 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $773.27 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $732.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $570.36 | 2019-2022 | |
| Glaxosmithkline, LLC. | $531.53 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $489.72 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $477.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.85 | 2019-2023 | Glassia |
| Allergan, INC. | $375.49 | 2019-2020 | |
| Astellas Pharma US INC | $350.16 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $335.24 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $314.32 | 2024-2025 | Voquezna |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tze Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.